

# Journal of Medicinal Chemistry



**About the Cover:**

Ribbon rendered illustration of the nuclear receptor heterodimer RXRa(cyan):PPAPRy (red) ligand binding domains bound with coactivator peptides (magenta) and agonist ligands (space-filling atoms where green is carbon, red is oxygen, and blue is nitrogen) (Haffner, C. D.; et al. *J. Med. Chem.* **2004**, *47*, 2010-2029).

[Download Cover](#)**In this issue:**

- » Miniperspectives:Advances in Type 2 Diabetes
- » Letters
- » Articles
- » Brief Articles


**Sort By:**

Page

**MINIPERSPECTIVES:ADVANCES IN TYPE 2 DIABETES****Novel “Second-Generation” Approaches for the Control of Type 2 Diabetes**

David P. Rotella

*Journal of Medicinal Chemistry* 2004, *47*, 17, 4111-4112 (**Perspective**)**Publication Date (Web):** July 20, 2004 First Page Full text PDF



## Diabetes Mellitus: Pathogenesis and Treatment Strategies

Jay S. Skyler

*Journal of Medicinal Chemistry* 2004, 47, 17, 4113-4117 (Perspective)

Publication Date (Web): July 20, 2004

 First Page

 Full text



 PDF

ADVERTISEMENT

VIRTUAL SPECIAL ISSUE

Glycoscience in  
Infectious Diseases

Infectious  
ACS Diseases



Brad R. Henke

*Journal of Medicinal Chemistry* 2004, 47, 17, 4118-4127 (**Perspective**)

Publication Date (Web): July 20, 2004

 First Page Full text PDF

## GLP-1:

His<sup>1</sup>-Ala-Glu-Gly<sup>10</sup>-Thr-Phe-Thr-Ser-Asp<sup>15</sup>-Val-Ser-Ser-Tyr-Leu<sup>20</sup>-Glu-Gly-Gln-Ala-Ala<sup>25</sup>-Lys-Glu-Phe-Ile-Ala<sup>30</sup>-Trp-Leu-Val-Lys-Gly-Arg-Gly<sup>37</sup>

## Exendin-4:


His<sup>1</sup>-Gly-Glu-Gly<sup>10</sup>-Thr-Phe-Thr-Ser-Asp<sup>15</sup>-Leu-Ser-Lys-Gln-Met<sup>22</sup>-Glu-Glu-Glu-Ala-Val<sup>25</sup>-Arg-Leu-Phe-Ile-Glu<sup>30</sup>-Trp-Leu-Lys-Asn-Gly-Gly-Pro<sup>37</sup>-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser

## Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes

Lotte Bjerre Knudsen

*Journal of Medicinal Chemistry* 2004, 47, 17, 4128-4134 (**Perspective**)

Publication Date (Web): July 20, 2004

 First Page Full text PDF

## Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes

<https://pubs.acs.org/toc/jmcmar/47/17>

5/19

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.